KIDS Stock Analysis: Orthopediatrics | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 501m USD | 12M Return: -17.1% | Charts, Fundamentals & Technical Analysis

Trauma Implants, Spinal Deformity, Sports Medicine, Bracing
Total Rating 30
Safety 71
Buy Signal -0.30
Medical Devices
Industry Rotation: +0.3
Market Cap: 501M
Avg Turnover: 3.07M
Risk 3d forecast
Volatility46.7%
VaR 5th Pctl8.01%
VaR vs Median4.14%
Reward TTM
Sharpe Ratio-0.26
Rel. Str. IBD45.4
Rel. Str. Peer Group52.1
Character TTM
Beta0.987
Beta Downside1.056
Hurst Exponent0.481
Drawdowns 3y
Max DD64.93%
CAGR/Max DD-0.36
CAGR/Mean DD-0.57
EPS (Earnings per Share) EPS (Earnings per Share) of KIDS over the last years for every Quarter: "2021-06": -0.11, "2021-09": -0.15, "2021-12": -0.24, "2022-03": -0.3, "2022-06": -0.17, "2022-09": -0.05, "2022-12": -0.35, "2023-03": -0.29, "2023-06": -0.19, "2023-09": -0.13, "2023-12": -0.23, "2024-03": -0.34, "2024-06": -0.23, "2024-09": -0.34, "2024-12": -0.29, "2025-03": -0.39, "2025-06": -0.11, "2025-09": -0.24, "2025-12": -0.26, "2026-03": -0.42,
Last SUE: 0.26
Qual. Beats: 0
Revenue Revenue of KIDS over the last years for every Quarter: 2021-06: 26.695, 2021-09: 25.079, 2021-12: 24.813, 2022-03: 23.417, 2022-06: 32.928, 2022-09: 34.95, 2022-12: 30.994, 2023-03: 31.588, 2023-06: 39.559, 2023-09: 39.972, 2023-12: 37.613, 2024-03: 44.685, 2024-06: 52.802, 2024-09: 54.573, 2024-12: 52.667, 2025-03: 52.411, 2025-06: 61.082, 2025-09: 61.25, 2025-12: 61.605, 2026-03: 59.362,
Rev. CAGR: 25.20%
Rev. Trend: 98.7%
Last SUE: 0.77
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Fakeout

Tailwinds

No distinct edge detected

Seasonality

Not enough history
Description: KIDS Orthopediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) is a medical device company that designs, develops, and markets anatomically appropriate implants, instruments, and braces specifically for children with orthopedic conditions. Its product portfolio spans three main categories: pediatric trauma and deformity correction, scoliosis procedures, and sports medicine and other products, featuring a wide range of branded systems and platforms such as PediLoc, RESPONSE Spine, the Fassier-Duval Telescopic Intramedullary System, and the Boston Brace 3D. The company serves the pediatric orthopedic market, including pediatric orthopedic surgeons and caregivers, in both the United States and international markets. Founded in 2006 and headquartered in Warsaw, Indiana, OrthoPediatrics is a small-cap ($501M USD) health care supplies company that listed on NASDAQ in October 2017.

OrthoPediatrics operates in a specialized niche within the broader orthopedic device industry, which is largely dominated by large-cap manufacturers focused on adult populations. As a pure-play pediatric orthopedic company, its business model depends on surgeon relationships, recurring procedure-based revenue, and ongoing regulatory clearances and approvals from the U.S. Food and Drug Administration (FDA) for new and modified devices. Its broad product portfolio, which spans implants, instruments, and bracing, allows it to serve a wide range of procedures and patient ages within childrens orthopedics.

Headlines to Watch Out For
  • Scoliosis and trauma segment revenue drives double-digit domestic growth
  • Operating losses persist as salesforce expansion and acquisitions pressure margins
  • International expansion lifts geographic revenue mix with European momentum
Piotroski VR-10 (Strict) 1.5
Net Income: -39.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA 5.33 > 1.0
NWC/Revenue: 81.66% < 20% (prev 91.58%; Δ -9.91% < -1%)
CFO/TA -0.01 > 3% & CFO -3.98m > Net Income -39.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.21 > 1.5 & < 3
Outstanding Shares: last quarter (23.7m) vs 12m ago 1.95% < -2%
Gross Margin: 73.07% > 18% (prev 72.81%; Δ 0.26% > 0.5%)
Asset Turnover: 50.04% > 50% (prev 45.18%; Δ 4.86% > 0%)
Interest Coverage Ratio: -4.08 > 6 (EBIT TTM -28.4m / Interest Expense TTM 6.97m)
Altman Z'' 2.52
A: 0.40 (Total Current Assets 245.9m - Total Current Liabilities 47.2m) / Total Assets 502.2m
B: -0.57 (Retained Earnings -285.9m / Total Assets 502.2m)
C: -0.06 (EBIT TTM -28.4m / Avg Total Assets 486.2m)
D: 2.07 (Book Value of Equity 338.7m / Total Liabilities 163.5m)
Altman-Z'' = 2.52 = A
Beneish M -2.84
DSRI: 1.08 (Receivables 54.4m/44.0m, Revenue 243.3m/212.5m)
GMI: 1.00 (GM 72.81% / 73.07%)
AQI: 1.05 (AQ_t 0.41 / AQ_t-1 0.39)
SGI: 1.15 (Revenue 243.3m / 212.5m)
TATA: -0.07 (NI -39.7m - CFO -3.98m) / TA 502.2m)
Beneish M = -2.84 (Cap -4..+1) = A
What is the price of KIDS shares?

As of July 25, 2026, the stock is trading at USD 18.87 with a total of 138,420 shares traded. Over the past week, the price has changed by -1.80%, over one month by -1.41%, over three months by +16.55% and over the past year by -17.09%.

Current recommended Stop Loss: 17.40 (which is 7.8% or 1.4 ATR below the current price).

Is KIDS a buy, sell or hold?

Orthopediatrics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy KIDS.

  • StrongBuy: 3
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the KIDS price?
Analysts Target Price 25 32.5%
Orthopediatrics (KIDS) - Fundamental Data Overview as of 23 July 2026
Market Cap USD = 500.6m (500.6m USD * 1.0 USD.USD)
P/S = 2.0576
P/B = 1.4772
Revenue TTM = 243.3m USD
EBIT TTM = -28.4m USD
EBITDA TTM = -6.63m USD
Long Term Debt = 100.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.93m USD (from shortTermDebt, last quarter)
Debt = 106.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 320k
Net Debt = 55.7m USD (calculated: Debt 106.6m - CCE 50.9m)
Enterprise Value = 556.3m USD (500.6m + Debt 106.6m - CCE 50.9m)
Interest Coverage Ratio = -4.08 (Ebit TTM -28.4m / Interest Expense TTM 6.97m)
EV/FCF = -44.07x (Enterprise Value 556.3m / FCF TTM -12.6m)
FCF Yield = -2.27% (FCF TTM -12.6m / Enterprise Value 556.3m)
FCF Margin = -5.19% (FCF TTM -12.6m / Revenue TTM 243.3m)
Net Margin = -16.31% (Net Income TTM -39.7m / Revenue TTM 243.3m)
Gross Margin = 73.07% ((Revenue TTM 243.3m - Cost of Revenue TTM 65.5m) / Revenue TTM)
Gross Margin QoQ = 73.09% (prev 73.22%)
Tobins Q-Ratio = 1.11 (Enterprise Value 556.3m / Total Assets 502.2m)
Interest Expense / Debt = 6.54% (Interest Expense 6.97m / Debt 106.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -22.5m (EBIT -28.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.21 (Total Current Assets 245.9m / Total Current Liabilities 47.2m)
Debt / Equity = 0.31 (Debt 106.6m / totalStockholderEquity, last quarter 338.7m)
 Debt / EBITDA = -8.41 (negative EBITDA) (Net Debt 55.7m / EBITDA -6.63m)
 Debt / FCF = -4.41 (negative FCF - burning cash) (Net Debt 55.7m / FCF TTM -12.6m)
 Total Stockholder Equity = 347.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.16% (Net Income -39.7m / Total Assets 502.2m)
RoE = -11.42% (Net Income TTM -39.7m / Total Stockholder Equity 347.5m)
RoCE = -6.34% (EBIT -28.4m / Capital Employed (Equity 347.5m + L.T.Debt 100.4m))
 RoIC = -5.04% (negative operating profit) (NOPAT -22.5m / Invested Capital 445.8m)
 WACC = 8.70% (E(500.6m)/V(607.2m) * Re(9.45%) + D(106.6m)/V(607.2m) * Rd(6.54%) * (1-Tc(0.21)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.14 | Cagr: 1.78%
 [DCF] Fair Price = unknown (Cash Flow -12.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.26 | # QB: 0
Revenue Correlation: 98.68 | Revenue CAGR: 25.20% | SUE: 0.77 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.28 | Chg30d=+0.00% | Revisions=-17% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+0.00% | Revisions=-17% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.05 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=-5.2% | GrowthRev=+12.2%
EPS next Year (2027-12-31): EPS=-0.68 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=+35.3% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: +0% (up=6, down=6)